VSIR and COVID-19: Enrichment analysis of the COVID-19 immune profile indicates that anti-VISTA agonists may suppress the COVID-19 inflammatory signature, as the VISTA agonist downregulated almost 40% of COVID-19 hallmark immune genes (53).